Clinical Infectious Diseases
AZD7442 (Tixagevimab/Cilgavimab) for Post-exposure Prophylaxis of Symptomatic COVID-19
Myron J. Levin
1
,
Andrew Ustianowski
2
,
Steven Thomas
3
,
Alison Templeton
4
,
Yuan Yuan
3
,
Seth Seegobin
4
,
Catherine F. Houlihan
5, 6
,
Ibrahim Menendez Perez
7
,
Simon Pollett
8, 9
,
Rosalinda H. Arends
10
,
Rohini Beavon
11
,
Kanika Dey
12
,
Pedro Garbes
12
,
Elizabeth J. Kelly
13
,
Gavin C K W Koh
11
,
STEFAN IVANOV
14
,
Karen A. Near
12
,
Audrey Sharbaugh
15
,
Katie Streicher
13
,
Menelas N. Pangalos
16
,
Mark T Esser
17
1
University of Colorado Denver School of Medicine , Aurora, Colorado , USA
|
2
North Manchester General Hospital , Manchester , United Kingdom
|
3
Biometrics, Vaccines and Immune Therapies, BioPharmaceuticals Research and Development, AstraZeneca , Gaithersburg, Maryland , USA
|
4
Biometrics, Vaccines and Immune Therapies, BioPharmaceuticals Research and Development, AstraZeneca , Cambridge , United Kingdom
|
7
Project 4 Research , Miami, Florida , USA
|
9
Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc , Bethesda, Maryland , USA
|
10
Clinical Pharmacology and Quantitative Pharmacology, Vaccines and Immune Therapies, BioPharmaceuticals Research and Development, AstraZeneca , Gaithersburg, Maryland , USA
|
11
Clinical Development, Vaccines and Immune Therapies, BioPharmaceuticals Research and Development, AstraZeneca , Cambridge , United Kingdom
|
12
Clinical Development, Vaccines and Immune Therapies, BioPharmaceuticals Research and Development, AstraZeneca , Gaithersburg, Maryland , USA
|
13
Translational Medicine, Vaccines and Immune Therapies, BioPharmaceuticals Research and Development, AstraZeneca , Gaithersburg, Maryland , USA
|
14
Clinical Development, Vaccines and Immune Therapies, BioPharmaceuticals Research and Development, AstraZeneca , Gothenburg , Sweden
|
15
Clinical Development, Vaccines and Immune Therapies, BioPharmaceuticals Research and Development, AstraZeneca , Durham, North Carolina , USA
|
16
BioPharmaceuticals Research and Development, AstraZeneca , Cambridge , United Kingdom
|
17
Vaccines and Immune Therapies, BioPharmaceuticals Research and Development, AstraZeneca , Gaithersburg, Maryland , USA
|
Publication type: Journal Article
Publication date: 2022-11-22
Journal:
Clinical Infectious Diseases
Quartile SCImago
Q1
Quartile WOS
Q1
Impact factor: 11.8
ISSN: 10584838, 15376591
Abstract
Background
We report primary results of a phase 3 trial of AZD7442 (tixagevimab/cilgavimab) for post-exposure prophylaxis to prevent symptomatic coronavirus disease 2019 (COVID-19)
Methods
Adults without prior SARS-CoV-2 infection or COVID-19 vaccination were enrolled within 8 days of exposure to a SARS-CoV-2–infected individual and randomized 2:1 to a single 300-mg AZD7442 dose (one 1.5-mL intramuscular injection each of tixagevimab and cilgavimab consecutively) or placebo. Primary endpoints were safety and first post-dose SARS-CoV-2 reverse-transcription–polymerase-chain-reaction (RT-PCR)–positive symptomatic COVID-19 event before day 183.
Results
1121 participants were randomized and dosed (mean age 46 years; 49% females; AZD7442, n=749; placebo, n=372). Median (range) follow-up was 49 (5–115) and 48 (20–113) days for AZD7442 and placebo, respectively. Adverse events occurred in 162/749 (21.6%) and 111/372 (29.8%) participants with AZD7442 and placebo, respectively, mostly mild/moderate. RT-PCR–positive symptomatic COVID-19 occurred in 23/749 (3.1%) and 17/372 (4.6%) AZD7442- and placebo-treated participants, respectively (relative risk reduction 33.3%; 95% confidence interval [CI] –25.9 to 64.7; P=.21). In predefined subgroup analyses of 1073 (96%) participants who were SARS-CoV-2 RT-PCR–negative (n=974 [87%]) or missing an RT-PCR result (n=99 [9%]) at baseline, AZD7442 reduced RT-PCR–positive symptomatic COVID-19 by 73.2% (95% CI 27.1 to 90.1) versus placebo.
Conclusions
This study did not meet the primary efficacy endpoint of post-exposure prevention of symptomatic COVID-19 with AZD7442 versus placebo. However, predefined analysis of participants who were SARS-CoV-2 RT-PCR–negative or missing an RT-PCR result at baseline support a role for AZD7442 in preventing symptomatic COVID-19.
Top-30
Citations by journals
|
1
|
|
|
Expert Opinion on Biological Therapy
1 publication, 4.35%
|
|
|
Nauchno-Prakticheskaya Revmatologiya
1 publication, 4.35%
|
|
|
International Journal of Infectious Diseases
1 publication, 4.35%
|
|
|
Open Forum Infectious Diseases
1 publication, 4.35%
|
|
|
Journal of the Formosan Medical Association
1 publication, 4.35%
|
|
|
Frontiers in Cellular and Infection Microbiology
1 publication, 4.35%
|
|
|
Pharmaceuticals
1 publication, 4.35%
|
|
|
Transplant Infectious Disease
1 publication, 4.35%
|
|
|
European Journal of Medical Research
1 publication, 4.35%
|
|
|
International Journal of Rheumatic Diseases
1 publication, 4.35%
|
|
|
Journal of the Pediatric Infectious Diseases Society
1 publication, 4.35%
|
|
|
Bioanalysis
1 publication, 4.35%
|
|
|
Viruses
1 publication, 4.35%
|
|
|
Antimicrobial Agents and Chemotherapy
1 publication, 4.35%
|
|
|
Microorganisms
1 publication, 4.35%
|
|
|
Leukemia and Lymphoma
1 publication, 4.35%
|
|
|
Cell Chemical Biology
1 publication, 4.35%
|
|
|
Infectious Diseases and Therapy
1 publication, 4.35%
|
|
|
Clinical Microbiology Reviews
1 publication, 4.35%
|
|
|
Vaccines
1 publication, 4.35%
|
|
|
Russian Chemical Reviews
1 publication, 4.35%
|
|
|
1
|
Citations by publishers
|
1
2
3
4
|
|
|
Multidisciplinary Digital Publishing Institute (MDPI)
4 publications, 17.39%
|
|
|
Taylor & Francis
3 publications, 13.04%
|
|
|
Elsevier
3 publications, 13.04%
|
|
|
Cold Spring Harbor Laboratory
2 publications, 8.7%
|
|
|
Oxford University Press
2 publications, 8.7%
|
|
|
Wiley
2 publications, 8.7%
|
|
|
Springer Nature
2 publications, 8.7%
|
|
|
American Society for Microbiology
2 publications, 8.7%
|
|
|
Mediar Press
1 publication, 4.35%
|
|
|
Frontiers Media S.A.
1 publication, 4.35%
|
|
|
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii
1 publication, 4.35%
|
|
|
1
2
3
4
|
- We do not take into account publications without a DOI.
- Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
- Statistics recalculated weekly.
{"yearsCitations":{"type":"bar","data":{"show":true,"labels":[2023,2024],"ids":[0,0],"codes":[0,0],"imageUrls":["",""],"datasets":[{"label":"Citations number","data":[9,14],"backgroundColor":["#3B82F6","#3B82F6"],"percentage":["39.13","60.87"],"barThickness":null}]},"options":{"indexAxis":"x","maintainAspectRatio":true,"scales":{"y":{"ticks":{"precision":0,"autoSkip":false,"font":{"family":"Montserrat"},"color":"#000000"},"stacked":false},"x":{"ticks":{"stepSize":1,"precision":0,"font":{"family":"Montserrat"},"color":"#000000"},"stacked":false}},"plugins":{"legend":{"position":"top","labels":{"font":{"family":"Montserrat"},"color":"#000000"}},"title":{"display":true,"text":"Citations per year","font":{"size":24,"family":"Montserrat","weight":600},"color":"#000000"}}}},"journals":{"type":"bar","data":{"show":true,"labels":["Expert Opinion on Biological Therapy","Nauchno-Prakticheskaya Revmatologiya","International Journal of Infectious Diseases","Open Forum Infectious Diseases","Journal of the Formosan Medical Association","Frontiers in Cellular and Infection Microbiology","Pharmaceuticals","Transplant Infectious Disease","European Journal of Medical Research","International Journal of Rheumatic Diseases","Journal of the Pediatric Infectious Diseases Society","Bioanalysis","Viruses","Antimicrobial Agents and Chemotherapy","Microorganisms","Leukemia and Lymphoma","Cell Chemical Biology","Infectious Diseases and Therapy","Clinical Microbiology Reviews","Vaccines","Russian Chemical Reviews"],"ids":[10768,21989,22,14565,11325,21709,1203,11926,17554,8361,2475,15951,2455,17567,6197,7830,4893,19665,8942,24868,23802],"codes":[0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0],"imageUrls":["\/storage\/images\/resized\/5YZtvLvkPZuc2JHOaZsjCvGSHFCuC3drUwN3YAc5_medium.webp","","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/yNSijlgQghQF53VZuyFLA30CKDe4j3HK74Vtpnxa_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/4QWA67eqfcfyOiA8Wk7YnqroHFqQbTsmDJUYTCTg_medium.webp","\/storage\/images\/resized\/MjH1ITP7lMYGxeqUZfkt2BnVLgjkk413jwBV97XX_medium.webp","\/storage\/images\/resized\/bRyGpdm98BkAUYiK1YFNpl5Z7hPu6Gd87gbIeuG3_medium.webp","\/storage\/images\/resized\/voXLqlsvTwv5p3iMQ8Dhs95nqB4AXOG7Taj7G4ra_medium.webp","\/storage\/images\/resized\/bRyGpdm98BkAUYiK1YFNpl5Z7hPu6Gd87gbIeuG3_medium.webp","\/storage\/images\/resized\/yNSijlgQghQF53VZuyFLA30CKDe4j3HK74Vtpnxa_medium.webp","\/storage\/images\/resized\/AN2jnDN59NmKaS4CWLHAGstADL2DbnatQScsFA6C_medium.webp","\/storage\/images\/resized\/MjH1ITP7lMYGxeqUZfkt2BnVLgjkk413jwBV97XX_medium.webp","\/storage\/images\/resized\/VPE7q24PXoHr5SS2SqfEgxccSMUxWLfZINOX60uo_medium.webp","\/storage\/images\/resized\/MjH1ITP7lMYGxeqUZfkt2BnVLgjkk413jwBV97XX_medium.webp","\/storage\/images\/resized\/5YZtvLvkPZuc2JHOaZsjCvGSHFCuC3drUwN3YAc5_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/voXLqlsvTwv5p3iMQ8Dhs95nqB4AXOG7Taj7G4ra_medium.webp","\/storage\/images\/resized\/VPE7q24PXoHr5SS2SqfEgxccSMUxWLfZINOX60uo_medium.webp","\/storage\/images\/resized\/MjH1ITP7lMYGxeqUZfkt2BnVLgjkk413jwBV97XX_medium.webp","\/storage\/images\/resized\/9Mus3KG1Tkd7Bwaurt8H3RwWh0CxRlGoO6ng9UK1_medium.webp"],"datasets":[{"label":"","data":[1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1],"backgroundColor":["#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6"],"percentage":[4.35,4.35,4.35,4.35,4.35,4.35,4.35,4.35,4.35,4.35,4.35,4.35,4.35,4.35,4.35,4.35,4.35,4.35,4.35,4.35,4.35],"barThickness":13}]},"options":{"indexAxis":"y","maintainAspectRatio":false,"scales":{"y":{"ticks":{"precision":0,"autoSkip":false,"font":{"family":"Montserrat"},"color":"#000000"},"stacked":false},"x":{"ticks":{"stepSize":null,"precision":0,"font":{"family":"Montserrat"},"color":"#000000"},"stacked":false}},"plugins":{"legend":{"position":"top","labels":{"font":{"family":"Montserrat"},"color":"#000000"}},"title":{"display":true,"text":"Journals","font":{"size":24,"family":"Montserrat","weight":600},"color":"#000000"}}}},"publishers":{"type":"bar","data":{"show":true,"labels":["Multidisciplinary Digital Publishing Institute (MDPI)","Taylor & Francis","Elsevier","Cold Spring Harbor Laboratory","Oxford University Press","Wiley","Springer Nature","American Society for Microbiology","Mediar Press","Frontiers Media S.A.","Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii"],"ids":[202,18,17,6909,19,11,8,142,9275,208,9422],"codes":[0,0,0,0,0,0,0,0,0,0,0],"imageUrls":["\/storage\/images\/resized\/MjH1ITP7lMYGxeqUZfkt2BnVLgjkk413jwBV97XX_medium.webp","\/storage\/images\/resized\/5YZtvLvkPZuc2JHOaZsjCvGSHFCuC3drUwN3YAc5_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/hg4jJjT8wVGtHstBCc0zk465Mg9pLx3G4odCDOqE_medium.webp","\/storage\/images\/resized\/yNSijlgQghQF53VZuyFLA30CKDe4j3HK74Vtpnxa_medium.webp","\/storage\/images\/resized\/bRyGpdm98BkAUYiK1YFNpl5Z7hPu6Gd87gbIeuG3_medium.webp","\/storage\/images\/resized\/voXLqlsvTwv5p3iMQ8Dhs95nqB4AXOG7Taj7G4ra_medium.webp","\/storage\/images\/resized\/VPE7q24PXoHr5SS2SqfEgxccSMUxWLfZINOX60uo_medium.webp","","\/storage\/images\/resized\/4QWA67eqfcfyOiA8Wk7YnqroHFqQbTsmDJUYTCTg_medium.webp","\/storage\/images\/resized\/9Mus3KG1Tkd7Bwaurt8H3RwWh0CxRlGoO6ng9UK1_medium.webp"],"datasets":[{"label":"","data":[4,3,3,2,2,2,2,2,1,1,1],"backgroundColor":["#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6"],"percentage":[17.39,13.04,13.04,8.7,8.7,8.7,8.7,8.7,4.35,4.35,4.35],"barThickness":13}]},"options":{"indexAxis":"y","maintainAspectRatio":false,"scales":{"y":{"ticks":{"precision":0,"autoSkip":false,"font":{"family":"Montserrat"},"color":"#000000"},"stacked":false},"x":{"ticks":{"stepSize":null,"precision":0,"font":{"family":"Montserrat"},"color":"#000000"},"stacked":false}},"plugins":{"legend":{"position":"top","labels":{"font":{"family":"Montserrat"},"color":"#000000"}},"title":{"display":true,"text":"Publishers","font":{"size":24,"family":"Montserrat","weight":600},"color":"#000000"}}}},"yearsCitationsQuartiles":{"type":"bar","data":{"show":true,"labels":[2023,2024],"ids":[],"codes":[],"imageUrls":[],"datasets":[{"label":"Q4","backgroundColor":"rgb(221,90,78)","data":[1,0],"percentage":["4.35","0"]},{"label":"Q3","backgroundColor":"rgb(251, 163,83)","data":[0,1],"percentage":["0","4.35"]},{"label":"Q2","backgroundColor":"rgb(232, 213, 89)","data":[1,5],"percentage":["4.35","21.74"]},{"label":"Q1","backgroundColor":"rgb(164, 207, 99)","data":[5,8],"percentage":["21.74","34.78"]},{"label":"Quartile not defined","backgroundColor":"#E5E7EB","data":[2,0],"percentage":["8.7","0"]}]},"options":{"indexAxis":"x","maintainAspectRatio":true,"scales":{"y":{"ticks":{"precision":0,"autoSkip":false,"font":{"family":"Montserrat"},"color":"#000000"},"stacked":true},"x":{"ticks":{"stepSize":1,"precision":0,"font":{"family":"Montserrat"},"color":"#000000"},"stacked":true}},"plugins":{"legend":{"position":"top","labels":{"font":{"family":"Montserrat"},"color":"#000000"}},"title":{"display":true,"text":"Citations quartiles by SCImago per year","font":{"size":24,"family":"Montserrat","weight":600},"color":"#000000"}}}},"yearsCitationsQuartilesWs":{"type":"bar","data":{"show":true,"labels":[2023,2024],"ids":[],"codes":[],"imageUrls":[],"datasets":[{"label":"Q4","backgroundColor":"rgb(221,90,78)","data":[0,0],"percentage":["0","0"]},{"label":"Q3","backgroundColor":"rgb(251, 163,83)","data":[1,3],"percentage":["4.35","13.04"]},{"label":"Q2","backgroundColor":"rgb(232, 213, 89)","data":[3,6],"percentage":["13.04","26.09"]},{"label":"Q1","backgroundColor":"rgb(164, 207, 99)","data":[2,5],"percentage":["8.7","21.74"]},{"label":"Quartile not defined","backgroundColor":"#E5E7EB","data":[3,0],"percentage":["13.04","0"]}]},"options":{"indexAxis":"x","maintainAspectRatio":true,"scales":{"y":{"ticks":{"precision":0,"autoSkip":false,"font":{"family":"Montserrat"},"color":"#000000"},"stacked":true},"x":{"ticks":{"stepSize":1,"precision":0,"font":{"family":"Montserrat"},"color":"#000000"},"stacked":true}},"plugins":{"legend":{"position":"top","labels":{"font":{"family":"Montserrat"},"color":"#000000"}},"title":{"display":true,"text":"Citations quartiles by WoS per year","font":{"size":24,"family":"Montserrat","weight":600},"color":"#000000"}}}}}
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
Cite this
GOST |
RIS |
BibTex
Cite this
GOST
Copy
Levin M. J. et al. AZD7442 (Tixagevimab/Cilgavimab) for Post-exposure Prophylaxis of Symptomatic COVID-19 // Clinical Infectious Diseases. 2022.
GOST all authors (up to 50)
Copy
Levin M. J., Ustianowski A., Thomas S., Templeton A., Yuan Y., Seegobin S., Houlihan C. F., Menendez Perez I., Pollett S., Arends R. H., Beavon R., Dey K., Garbes P., Kelly E. J., Koh G. C. K. W., IVANOV S., Near K. A., Sharbaugh A., Streicher K., Pangalos M. N., Esser M. T. AZD7442 (Tixagevimab/Cilgavimab) for Post-exposure Prophylaxis of Symptomatic COVID-19 // Clinical Infectious Diseases. 2022.
Cite this
RIS
Copy
TY - JOUR
DO - 10.1093/cid/ciac899
UR - https://doi.org/10.1093/cid/ciac899
TI - AZD7442 (Tixagevimab/Cilgavimab) for Post-exposure Prophylaxis of Symptomatic COVID-19
T2 - Clinical Infectious Diseases
AU - Levin, Myron J.
AU - Ustianowski, Andrew
AU - Thomas, Steven
AU - Templeton, Alison
AU - Yuan, Yuan
AU - Seegobin, Seth
AU - Houlihan, Catherine F.
AU - Menendez Perez, Ibrahim
AU - Pollett, Simon
AU - Arends, Rosalinda H.
AU - Beavon, Rohini
AU - Dey, Kanika
AU - Garbes, Pedro
AU - Kelly, Elizabeth J.
AU - Koh, Gavin C K W
AU - IVANOV, STEFAN
AU - Near, Karen A.
AU - Sharbaugh, Audrey
AU - Streicher, Katie
AU - Pangalos, Menelas N.
AU - Esser, Mark T
PY - 2022
DA - 2022/11/22 00:00:00
PB - Oxford University Press
SN - 1058-4838
SN - 1537-6591
ER -
Cite this
BibTex
Copy
@article{2022_Levin,
author = {Myron J. Levin and Andrew Ustianowski and Steven Thomas and Alison Templeton and Yuan Yuan and Seth Seegobin and Catherine F. Houlihan and Ibrahim Menendez Perez and Simon Pollett and Rosalinda H. Arends and Rohini Beavon and Kanika Dey and Pedro Garbes and Elizabeth J. Kelly and Gavin C K W Koh and STEFAN IVANOV and Karen A. Near and Audrey Sharbaugh and Katie Streicher and Menelas N. Pangalos and Mark T Esser},
title = {AZD7442 (Tixagevimab/Cilgavimab) for Post-exposure Prophylaxis of Symptomatic COVID-19},
journal = {Clinical Infectious Diseases},
year = {2022},
publisher = {Oxford University Press},
month = {nov},
url = {https://doi.org/10.1093/cid/ciac899},
doi = {10.1093/cid/ciac899}
}